J T Hartmann
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer
Wittekind C, Nuver J, Nicolai N, Necchi A, Mayer F, Lotz J, Lorch A, Looijenga L, Laguna M, Krege S, Kollmannsberger C, Kliesch S, Huddart R, Oechsle K, Oldenburg J, Oosterhuis J, Winter C, Tandstad T, Souchon R, Sohaib A, Sedlmayer F, Schweyer S, Schrader M, Salvioni R, Rosti G, Rick O, Rajpert-De Meyts E, Powles T, Horwich A, Honecker F, Hentrich M, Daugaard G, Dahl A, Cohn-Cedermark G, Classen J, Clarke N, Cavallin-Stahl E, Cathomas R, Busch J, Bokemeyer C, Aparicio J, Altena R, Albers P, De Giorgi U, De Santis M, De Wit M, Heidenreich A, Hartmann J, Giwercman A, Gillessen S, Gietema J, Germá Lluch J, Fossa S, Fléchon A, Fizazi K, Fenner M, Dieckmann K, De Wit R, Beyer J. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 2012; 24:878-88.
14.11.2012Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer
14.11.2012Ann Oncol 2012; 24:878-88
Wittekind C, Nuver J, Nicolai N, Necchi A, Mayer F, Lotz J P, Lorch A, Looijenga L H J, Laguna M P, Krege S, Kollmannsberger C, Kliesch S, Huddart R A, Oechsle K, Oldenburg J, Oosterhuis J W, Winter C, Tandstad T, Souchon R, Sohaib A, Sedlmayer F, Schweyer S, Schrader M, Salvioni R, Rosti G, Rick O, Rajpert-De Meyts E, Powles T, Horwich A, Honecker F, Hentrich M, Daugaard G, Dahl A A, Cohn-Cedermark G, Classen J, Clarke N W, Cavallin-Stahl E, Cathomas R, Busch J, Bokemeyer C, Aparicio J, Altena R, Albers P, De Giorgi U, De Santis M, De Wit M, Heidenreich A, Hartmann J T, Giwercman A, Gillessen S, Gietema J A, Germá Lluch J R, Fossa S D, Fléchon A, Fizazi K, Fenner M, Dieckmann K P, De Wit R, Beyer J
A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer
Hartmann J, Kollmannsberger C, Cascorbi I, Mayer F, Schittenhelm M, Heeger S, Bokemeyer C. A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer. Invest New Drugs 2012; 31:661-8.
26.07.2012A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer
26.07.2012Invest New Drugs 2012; 31:661-8
Hartmann J T, Kollmannsberger C, Cascorbi I, Mayer F, Schittenhelm Marcus, Heeger S, Bokemeyer C
Management of late recurrence of a low-grade endometrial stromal sarcoma (LGESS): treatment with letrozole
Krauss K, Bachmann C, Hartmann J, Siegmann K, Sotlar K, Wallwiener D, Huober J. Management of late recurrence of a low-grade endometrial stromal sarcoma (LGESS): treatment with letrozole. Anticancer research 2007; 27:3477-80.
01.01.2007Management of late recurrence of a low-grade endometrial stromal sarcoma (LGESS): treatment with letrozole
01.01.2007Anticancer research 2007; 27:3477-80
Krauss K, Bachmann C, Hartmann J T, Siegmann K, Sotlar K, Wallwiener D, Huober Jens
An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
Hartmann J, Oechsle K, Huober J, Jakob A, Azemar M, Horger M, Kanz L, Bokemeyer C. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Investigational new drugs 2006; 24:249-53.
01.05.2006An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
01.05.2006Investigational new drugs 2006; 24:249-53
Hartmann J T, Oechsle K, Huober Jens, Jakob A, Azemar M, Horger M, Kanz L, Bokemeyer C